drugset / Trial / NCT00985543

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.

NCT00985543

Phase 1 Completed 22 enrolled Kirby Institute
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval, following administration to male and female HIV-negative healthy volunteers of: 1. Lopinavir/ritonavir 400/100 mg twice daily 2. Lopinavir/ritonavir 200/150 mg twice daily 3. Lopinavir/ritonavir 200/50 mg twice daily

Timeline

Start
2009-10
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lopinavir Other / unclassified 200 mg
Subject Lopinavir Other / unclassified 400 mg
Subject Ritonavir Other / unclassified 50 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified 150 mg

Indications